Skip to main content

alpha 1-antitrypsin

Generic: alpha 1-antitrypsin·Brand: Aralast, Glassia, Prolastin, Zemaira

alpha 1-antitrypsin: 2 clinical trials tracked.

alpha 1-antitrypsin evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about alpha 1-antitrypsin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 2 study sponsors
Clinical Trial Registry Records (2)

Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of SAR447537 (INBRX-101) Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

NCT05856331Registry updated 2025-08-11·Phase 2·SNY
Completed

Primary endpoint: Serum functional AAT (fAAT) levels at steady-state

InterventionalRandomizedquadruple99 enrolledStarted 2023-10Completion 2025-0850 sites · Australia, United StatesSanofi

Prospective Phase 3 Multi-center 2-Year Placebo Controlled Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation 80 mg/Day in Alpha-1 Antitrypsin Deficiency With Moderate and Severe Airflow Limitation Followed by a 2-Year Open Label Extension

NCT04204252Registry updated 2026-08-12·Phase 3·KMDA
Terminated

Primary endpoint: FEV1 post bronchodilator

InterventionalRandomizedquadruple98 enrolledStarted 2019-11Completion 2026-029 sites · Belgium, Finland, Ireland, Netherlands…Kamada, Ltd.